United States · Funded startup
Funding summaryUpdated 26 Oct 2026
$535Mraised across 4 rounds since 2011, from 4 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
BlackRock
F-Prime Capital
Pappas Ventures
Healthcap IX Advisor ABReported by globenewswire.comSEC filing: $75M sold, first sale Dec 2012
Reported by bizjournals.comSEC filing: $15M sold, first sale Jul 2012
Reported by finsmes.comSEC filing: $19M sold, first sale Jun 2011
From the SEC filings it signed: 7 on the team.
On the board, as filediBen D. AuspitzEran D. NadavMarten D. SteenWilliam D. Aliski
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
F-Prime CapitalFidelity BiosciencesAdage Capital ManagementPappas VenturesHealthcap IX Advisor ABBlackRock
TPGTPG Sourcing Advisors, LLCTPG Biotechnology PartnersMissing a round, or an investor who was in one? Tell us.
Ultragenyx Pharmaceutical's investors include F-Prime Capital, Fidelity Biosciences, Adage Capital Management, Pappas Ventures and Healthcap IX Advisor AB, and 4 more on record.
Ultragenyx Pharmaceutical has raised $535M across 4 rounds since 2011.
Ultragenyx Pharmaceutical's most recent round was a Debt of $400M in Nov 2025.
Its most recent round, $400M in Nov 2025, is also its largest on record.
Ultragenyx Pharmaceutical's first round on record, in Jun 2011, was backed by F-Prime Capital, Fidelity Biosciences and Pappas Ventures and 2 others.
Ultragenyx Pharmaceutical's latest named round is a Debt, in Nov 2025.
Ultragenyx Pharmaceutical is based in the United States.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States · 
